Terms: = Bone cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
316 results:
1. Favorable impact of pd1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T; Chittilappilly C; Pirich T; Neuditschko B; Hackner K; Lind J; Aksoy O; Graichen U; Klee S; Herzog F; Wiesner C; Errhalt P; Pecherstorfer M; Podar K; Vallet S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702145
[TBL] [Abstract] [Full Text] [Related]
2. New advances in the treatment of chondrosarcoma under the pd-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract] [Full Text] [Related]
3. Ultrasound-Triggered Azo Free Radicals for Cervical cancer Immunotherapy.
Wang Y; Lv B; Wang H; Ren T; Jiang Q; Qu X; Ni D; Qiu J; Hua K
ACS Nano; 2024 Apr; 18(17):11042-11057. PubMed ID: 38627898
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
5. pd-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract] [Full Text] [Related]
6. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract] [Full Text] [Related]
7. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-pd-1 sdAb for Osteosarcoma treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review).
Hiraga T
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963
[TBL] [Abstract] [Full Text] [Related]
9. pd-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
10. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.
Wei L; Meng J; Xiang D; Yang Q; Zhou Y; Xu L; Wang M; Chen J; Han Y
BMC Complement Med Ther; 2024 Jan; 24(1):67. PubMed ID: 38297292
[TBL] [Abstract] [Full Text] [Related]
11. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
Cheng D; Zhang Z; Liu D; Mi Z; Tao W; Fu J; Fan H
Cancer Immunol Immunother; 2024 Jan; 73(2):35. PubMed ID: 38280005
[TBL] [Abstract] [Full Text] [Related]
12. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis.
Chen Q; Zhao Y; Li P; Duan J; Fu X; Tang Y; Ma Y; Zhou Q
Skin Res Technol; 2024 Feb; 30(2):e13546. PubMed ID: 38279601
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant pd-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract] [Full Text] [Related]
14. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
15. A prospective, single-arm trial of pd-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
Li L; Chen L; Fan M; Tian Y; Ai H; Yan L; Li F; Lan M; Lai X; Huang Y; Xu P; Feng M; Lang J
Oral Oncol; 2024 Mar; 150():106695. PubMed ID: 38262250
[TBL] [Abstract] [Full Text] [Related]
16. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
[TBL] [Abstract] [Full Text] [Related]
17. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Ko B; Tao K; Brennan L; Rakhade S; Chan CX; Moone JY; Zhu R; Sher A; Wang S; Bracero Y; Fullerton B; McLellan B; Geskin LJ; Saenger YM
Melanoma Res; 2024 Apr; 34(2):134-141. PubMed ID: 38181115
[TBL] [Abstract] [Full Text] [Related]
18. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.
Ding M; Ran X; Qian S; Zhang Y; Wang Z; Dong M; Yang Z; Wu S; Feng X; Zhang J; Zhu L; Niu S; Zhang X
Aging (Albany NY); 2023 Dec; 15(24):15360-15381. PubMed ID: 38180104
[TBL] [Abstract] [Full Text] [Related]
19. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
[TBL] [Abstract] [Full Text] [Related]
20. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
[TBL] [Abstract] [Full Text] [Related]
[Next]
